WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Trilogy Home Healthcare
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Drug Target Review | January 15, 2020
Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...
MBC BioLabs | May 11, 2020
Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.Built specifically as a life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work virtually immediately. This is MBC BioLabs' third campus and its seco...
MEDTECH
Versantis | November 15, 2021
Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...
BioSpace | April 16, 2020
California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...
INDUSTRIAL IMPACT
Video
MEDICAL
Whitepaper
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE